Clinical Observation of Appatinib Combined with Systemic Chemotherapy for Liver Metastasis of Gastroenteropancreatic Neu- roendocrine Neoplasm
- VernacularTitle:阿帕替尼联合全身化疗用于胃肠胰神经内分泌肿瘤肝转移的临床观察
- Author:
Rui XIONG
1
;
Tao YIN
1
;
Chuanyi DUAN
1
;
Jianlong GAO
1
;
Jianxin JIANG
2
Author Information
1. Second Ward，Dept. of Hepatobiliary and Pancreatic Surgery，Hubei Provincial Tumor Hospital，Wuhan 430079，China
2. Dept. of Hepatobiliary Surgery，Hubei Provincial People’s Hospital，Wuhan 430060，China
- Publication Type:Journal Article
- Keywords:
Apatinib;
Systemic chemotherapy;
Etoposide;
Cisplatin;
Gastroenteropancreatic neuroendocrine neoplasm;
Liver metastasis;
Efficacy;
Safety
- From:
China Pharmacy
2019;30(6):821-824
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To observe the efficacy and safety of apatinib combined with systemic chemotherapy for hepatic metastasis of gastroenteropancreatic neuroendocrine neoplasms （GEP-NEN）. METHODS： Totally 60 patients with GEP-NEN in Hubei Provincial Tumor Hospital from Jan. 2016 to Jan. 2018 were randomly divided into systemic chemotherapy group， apatinib group and combination group， with 20 patients in each group. Systemic chemotherapy group was given Etoposide injection 80 mg/m2，once a day d1-5， intravenously+Cisplatin for injection 20 mg/m2，once a day d1-5，intravenously， every 3 weeks for a cycle. Apatinib group was given Apatinib mesylate tablets 0.5 g， once a day. Combination group received treatment as systemic chemotherapy group+apatinib group. All three groups were treated continuously for 3 months. The clinical efficacies of 3 groups were observed. The serum levels of tumor markers （CEA， NSE， CgA and CA19-9） before and after treatment， survival situation after treatment and the occurrence of ADR during treatment were also observed. RESULTS： The objective remission rate， disease control rate， median overall survival and survival rate of combination group were significantly higher or longer than those of systemic chemotherapy group and apatinib group. Median progression-free survival and the incidence of ADR were significantly shorter or lower than systemic chemotherapy group and apatinib group （P＜0.05）. After treatment， the levels of CEA， NSE， CgA and CA19-9 in 3 groups were significantly lower than before treatment， and combination group was significantly lower than systemic chemotherapy group and apatinib group （P＜0.05）. There was no statistical significance in above indexes between systemic chemotherapy group and apatinib group （P＞0.05）. CONCLUSIONS： Apatinib combined with systemic chemotherapy for liver metastasis of GEP-NEN is effective and safe， which can improve the level of serum tumor markers， prolong the survival time of patients and improve survival rate.
